What is the MedPacto Inc. stock price forecast?

MedPacto Inc. is currently trading at ₩3,595. View real-time AI analysis on Alpha Lenz.

What is MedPacto Inc. insider trading activity?

View the latest insider trading data for MedPacto Inc. on Alpha Lenz.

What is MedPacto Inc.'s P/E ratio?

MedPacto Inc.'s P/E ratio is -9.6.

MedPacto Inc.

KRX · 235980

₩3,595+135(+3.90%)Market closed

Ask about MedPacto Inc.'s future dividend policy...

Alpha Chat Insight

“MedPacto Inc. trades at a P/E of -9.6 (undervalued) with modest ROE of -24.7%.”

Ask for details →

Company Overview

MedPacto Inc. is a biotechnology company focused on the development and commercialization of innovative cancer therapies. Its primary aim is to improve cancer treatment outcomes by leveraging its expertise in signaling pathways and bioinformatics. MedPacto is deeply involved in the research and development of oncology drugs that modulate key pathways implicated in cancer progression and resistance. The company operates in the pharmaceutical and healthcare sectors and collaborates with leading research institutions to bolster its drug discovery efforts. MedPacto's role in the financial market is significant as it represents a critical intersection of biopharmaceutical innovation and investment, attracting attention from stakeholders interested in the potential growth and advancement of cancer therapeutics.

CEO김성진

Websitehttps://www.medpacto.com

SectorHealthcare

IndustryBiotechnology

Employees56

Company Statistics

FY 2025

Profile

₩123,219,059,995Market Cap

₩3,898,477,860Revenue

34.28MShares Out

56Employees

Margins

9.88%Gross

-300.21%EBITDA

-359.59%Operating

-328.61%Pre-Tax

-328.61%Net

Valuation

-9.62P/E

2.68P/B

31.61EV/Sales

-9.65EV/EBITDA

-9.04P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-23.41%ROA

-24.70%ROE

-23.20%ROIC

Financial Health

₩11,997,347,140Cash & Cash Equivalents

₩-9,316,124,600Net Debt

5.83%Debt/Equity

N/AInterest Cov